e-learning
resources
Stockholm 2007
Sunday 16.09.2007
Cellular and molecular aspects of pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effects of selective and unselective endothelin-receptor antagonists on prostacyclin synthase gene expression in pulmonary hypertension
S. Schroll, M. Arzt, D. Sebah, B. Stoelcker, A. Luchner, F. C. Blumberg, M. Pfeifer (Regensburg, Donaustauf, Recklinghausen, Germany)
Source:
Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension
Session:
Cellular and molecular aspects of pulmonary hypertension
Session type:
Electronic Poster Discussion
Number:
490
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Schroll, M. Arzt, D. Sebah, B. Stoelcker, A. Luchner, F. C. Blumberg, M. Pfeifer (Regensburg, Donaustauf, Recklinghausen, Germany). Effects of selective and unselective endothelin-receptor antagonists on prostacyclin synthase gene expression in pulmonary hypertension. Eur Respir J 2007; 30: Suppl. 51, 490
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Looking to the future: a new decade of pulmonary arterial hypertension therapy
Source: Eur Respir Rev 2011; 20: 262-269
Year: 2011
Successful transition from oral prostacyclin analogue (beraprost) to the selective endothelin receptor antagonist (sitaxsentan) therapy in pulmonary arterial hypertension
Source: Annual Congress 2007 - Pulmonary hypertension: diagnosis and treatment
Year: 2007
NTP42, an antagonist of the thromboxane receptor, attenuates experimentally-induced pulmonary arterial hypertension
Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench
Year: 2019
Effects of the NO donor molsidomine on prostacyclin synthase gene expression in rats with chronic hypoxic pulmonary hypertension
Source: Eur Respir J 2001; 18: Suppl. 33, 414s
Year: 2001
Dual-targeting of peripheral cannabinoid-1 receptors and inducible NO synthase in pulmonary fibrosis
Source: International Congress 2017 – Cellular signalling pathways in pulmonary fibrosis
Year: 2017
Effects of endothelial nitric oxide synthase enzyme, angiotensin converting enzyme and serotonin transporter genotypes on pulmonary hypertension in COPD
Source: Annual Congress 2010 - Pulmonary circulation I
Year: 2010
The use of combination therapy in pulmonary arterial hypertension: new developments
Source: Eur Respir Rev 2009; 18: 148-153
Year: 2009
Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension
Source: Eur Respir J 2004; 24: 1007-1010
Year: 2004
Dual endothelin receptor antagonism: setting standards in PAH
Source: Eur Respir Rev 2008; 17: 13-18
Year: 2007
Polymorphism of prostacyclin synthase gene in pulmonary hypertension
Source: Eur Respir J 2002; 20: Suppl. 38, 5s
Year: 2002
Inhalation of endothelin receptor blockers in pulmonary hypertension
Source: Annual Congress 2008 - Pulmonary hypertension I
Year: 2008
Combination of inhaled nitric oxide and an endothelin
A
-receptor antagonist in acute pulmonary thromboembolism
Source: Eur Respir J 2003; 22: Suppl. 45, 463s
Year: 2003
Differential action of beraprost isomers on prostacyclin (IP) receptors and PPARβ in pulmonary arteries
Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Year: 2015
Endothelin-a receptor antagonists reduce eNOS gene expression in rats with chronic hypoxic pulmonary hypertension
Source: Eur Respir J 2003; 22: Suppl. 45, 271s
Year: 2003
Effects of selective and non-selective cyclooxygenase inhibition on exhaled eicosanoids in COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 578s
Year: 2004
Endothelin receptor antagonists in pulmonary arterial hypertension
Source: Eur Respir J 2008; 31: 407-415
Year: 2008
Long-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy
Source: Eur Respir Rev 2009; 18: 253-259
Year: 2009
Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment
Source: Eur Respir J 2011; 38: 851-860
Year: 2011
Severe pulmonary hypertension in chronic lung disease. Long term effects on gas exchange of endothelin receptor antagonists or PDE5 inhibitors
Source: Annual Congress 2011 - Pulmonary hypertension in hypoxic lung disease
Year: 2011
Endothelin: setting the scene in PAH
Source: Eur Respir Rev 2008; 17: 3-7
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept